Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Thyroid Cancer, Papillary 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Pleuropulmonary blastoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphedema 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Duodenal Neoplasms 1Carcinoma, Lobular 1Anatomic Stage III Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × High-Energy Shock Waves × Clear all
NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

University of Southern California

Phase 1 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Mayo Clinic

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡